Increased number of shares and votes in Medivir
The number of shares and the number of votes in Medivir have changed as a result of a directed new issue as well as exercise of employee stock options.
Today, the last trading day of the month, there are in total 28,593,229 shares, divided into 660,000 class A shares and 27,933,229 class B shares, and 34,533,229 votes in Medivir.
The above information has been made public in accordance with the Financial Instruments Trading Act. The information was submitted for publication at 07.00 am (CET) on 30 December 2010.
| For more information about Medivir, please contact: | |
| Rein Piir, CFO & VP Investor Relations | Office: +46 8 546 831 23 Mobile: +46 708 537 292 |
About Medivir
Medivir is a research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world-class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product, an innovative treatment for cold sores.
Xerese™/Xerclear® is a treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and by prescription sold by Meda in North America. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.
Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.
For more information about Medivir, please visit the Company’s website: www.medivir.se
Tags: